Pure Global AI
NCT06415045Not yet recruiting

A Study in Healthy People to Test How BI 1015550 is Taken up in the Body When Given With or Without Food

The Effect of Food on the Pharmacokinetics of BI 1015550 (Formulation C2) Following Single Oral Dose Administration in Healthy Subjects (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Design)
Boehringer IngelheimPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Healthy
Drug/Device/Intervention
BI 1015550
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Boehringer Ingelheim
Timeline & enrollment
Phase
Phase 1
Start date
May 28, 2024
End date
Jul 24, 2024
Enrollment
18 participants
Primary outcome

Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC 0-tz ),Maximum measured concentration of the analyte in plasma (Cmax)

Summary

The main objective is to investigate the effect of food on the pharmacokinetics of BI 1015550
 Formulation C2.

ICD-10 classifications
ObesitySeeking and accepting physical, nutritional and chemical interventions known to be hazardous and harmfulHealthy person accompanying sick personLifestyle-related conditionMalnutrition
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06415045
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06415045 through Pure Global AI's free database. This Phase 1 trial is sponsored by Boehringer Ingelheim and is currently Not yet recruiting. The study focuses on Healthy. Target enrollment is 18 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.